Process quality measures and asthma exacerbations in the Medicaid population - 15/08/11
Abstract |
Background |
Asthma quality assessment often focuses on controller medication use, yet claims-based studies find conflicting associations between this care process and clinical outcomes.
Objective |
We sought to compare the association between 3 controller-based quality measures and asthma exacerbations to gain better understanding of how processes of care are related to clinical outcomes.
Methods |
Identifying a cohort of Medicaid beneficiaries with persistent asthma by using Healthcare Effectiveness Data and Information Set (HEDIS) criteria for asthma in 2001–2002 in California and New York, we assessed 3 asthma quality metrics in 2002: (1) the current HEDIS measure of at least 1 controller medication filling; (2) at least 4 controller medication prescription fillings; and (3) a controller-to-total asthma medication ratio of at least 0.5. We calculated the odds of having an asthma exacerbation in 2003 as a function of performance on each quality metric, adjusting for race, sex, age, and prior outpatient and acute care use for asthma.
Results |
Of 90,909 subjects with persistent asthma in California (48.1%) and New York (51.9%), those who obtained at least 1 or at least 4 controller medications had increased likelihood of poor outcomes (adjusted odds ratios, 1.80 [95% CI, 1.73–1.87] and 1.44 [95% CI 1.40–1.48], respectively). Beneficiaries meeting the controller-to-total asthma medication ratio measure were 23.0% less likely to have exacerbations (adjusted odds ratio, 0.77 [95% CI, 0.75-0.80]).
Conclusions |
A higher controller medication ratio indicated a lower likelihood of asthma exacerbations, whereas assessing the number of controller medication–dispensing events was associated with a higher odds of exacerbation.
El texto completo de este artículo está disponible en PDF.Key words : Asthma, quality of care, Healthcare Effectiveness Data and Information Set, Medicaid
Abbreviations used : ED, HEDIS, NCQA, OR
Esquema
P. L. Y. is supported by a training grant from the Philadelphia Veterans Affairs Medical Center and the Robert Wood Johnson Clinical Scholars Program. R. M. W is supported in part by a Veterans Affairs HSR&D Career Development Award. The study was supported by pilot grant funding from the Leonard Davis Institute of Health Economics and resources supported by the Clinical and Translational Science Awards (UL1-RR024134). |
|
Disclosure of potential conflict of interest: R. M. Werner receives research support from the Institute on Aging, the SGIM Williams Scholar Award, and the Agency for Healthcare Research and Quality and has provided legal consultation/expert witness testimony in cases related to outpatient management of suspected coronary artery disease. P. L. Yong has declared that he has no conflict of interest. |
Vol 124 - N° 5
P. 961-966 - novembre 2009 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?